Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

AHA Statement Highlights Gender Differences in PCI: Part II

AHA Statement Highlights Gender Differences in PCI: Part II In her previous installment (see AHA Statement Highlights Gender Differences in PCI: Part I (In J Interven Cardiol 18(4), p. 303; reprinted from) ATCT Proceedings, Vol. 2, Issue 2), Ms. White discussed the evidence for gender differences in PCI outcomes, as well as differing outcomes by device and clinical syndrome in her review of the consensus document, “Percutaneous Coronary Intervention and Adjunctive Pharmacology in Women: A Statement for Healthcare Professionals From the American Heart Association” ( Circulation;2005;111:940–953). The AHA statement, which reviewed over 2,000 publications from the medical literature, also discussed gender differences in pharmacology and opportunities for improving the evidence base and outcomes in women. Pharmacology‐Antiplatelet and Antithrombin Agents ACC/AHA guidelines recommend that aspirin (160–325 mg) be administered in the initial management of all patients with unstable angina/non‐ST‐segment myocardial infarction (UA/NSTEMI), acute MI, or suspected acute MI. Following this treatment protocol results in an estimated 23‐30% reduction in mortality. Despite the ACC/AHA guidelines and the documented clinical benefit, aspirin is underused in the secondary prevention of coronary artery disease (CAD) in high‐risk women. The thienopyridine agents, clopidogrel and ticlopidine, when given with aspirin, have been shown to reduce the rates of subacute stent thrombosis after stent implantation. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Interventional Cardiology Wiley

AHA Statement Highlights Gender Differences in PCI: Part II

WHITE, JENNIFER
Journal of Interventional Cardiology , Volume 18 (5) – Oct 1, 2005
Download PDF
2 pages

Loading next page...
 
/lp/wiley/aha-statement-highlights-gender-differences-in-pci-part-ii-UtufSYfp8E

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wiley
Copyright
Copyright © 2005 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0896-4327
eISSN
1540-8183
DOI
10.1111/j.1540-8183.2005.00060.x
pmid
16202110
Publisher site
See Article on Publisher Site

Abstract

In her previous installment (see AHA Statement Highlights Gender Differences in PCI: Part I (In J Interven Cardiol 18(4), p. 303; reprinted from) ATCT Proceedings, Vol. 2, Issue 2), Ms. White discussed the evidence for gender differences in PCI outcomes, as well as differing outcomes by device and clinical syndrome in her review of the consensus document, “Percutaneous Coronary Intervention and Adjunctive Pharmacology in Women: A Statement for Healthcare Professionals From the American Heart Association” ( Circulation;2005;111:940–953). The AHA statement, which reviewed over 2,000 publications from the medical literature, also discussed gender differences in pharmacology and opportunities for improving the evidence base and outcomes in women. Pharmacology‐Antiplatelet and Antithrombin Agents ACC/AHA guidelines recommend that aspirin (160–325 mg) be administered in the initial management of all patients with unstable angina/non‐ST‐segment myocardial infarction (UA/NSTEMI), acute MI, or suspected acute MI. Following this treatment protocol results in an estimated 23‐30% reduction in mortality. Despite the ACC/AHA guidelines and the documented clinical benefit, aspirin is underused in the secondary prevention of coronary artery disease (CAD) in high‐risk women. The thienopyridine agents, clopidogrel and ticlopidine, when given with aspirin, have been shown to reduce the rates of subacute stent thrombosis after stent implantation.

Journal

Journal of Interventional Cardiology – Wiley

Published: Oct 1, 2005

There are no references for this article.